BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

CORT upcoming catalysts

Corcept Therapeutics: 1 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 3 readout(s) and 2 FDA event(s). Subscribe to CORT (.ics).

Drugs: relacorilant, Nivolumab

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2Corcept Therapeutics CORTNCT03604198 Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing SyndromeCushing Syndromeactive not recruiting125

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-03-25FDA approvalapprovedCORCEPT THERAP CORTLIFYORLIApproved 2026-03-25: LIFYORLI (COPACKAGED) (NDA220641 ORIG1)
2026-01-28Complete response lettercomplete responseCorcept Therapeutics CORTrelacorilantCRL 2026-01-28: Corcept Therapeutics NDA 219398 (relacorilant capsules)

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10 est.P2Corcept Therapeutics CORTNCT05407324 Dazucorilant in Patients With Amyotrophic Lateral SclerosisAmyotrophic Lateral Sclerosisactive not recruiting279
2026-09 est.P1/P2Corcept Therapeutics CORTNCT07276373 Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid MalignanciesNeoplasmsrecruiting50
2026-02-13P2Corcept Therapeutics CORTNCT06108219 A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)Nonalcoholic Steatohepatitis (NASH); Metabolic Dysfunction-associated Steatohepatitis (MASH)completed175

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.